Abstract | BACKGROUND: METHODS: Data from the Resolute program (Resolute All Comers and Resolute International) were pooled and patients with R-ZES implantation were categorized by indication: STEMI (n=335), non-STEACS (n=1416), and SA (n=1260). RESULTS: Mean age was 59.8±11.3 years ( STEMI), 63.8±11.6 (non-STEACS), and 64.9±10.1 (SA). Fewer STEMI patients had diabetes (19.1% vs. 28.5% vs. 29.2%; P<0.001), prior MI (11.3% vs. 27.2% vs. 29.4%; P<0.001), or previous revascularization (11.3% vs. 27.9% vs. 37.6%; P<0.001). Two-year definite/probable stent thrombosis occurred in 2.4% ( STEMI), 1.2% (non-STEACS) and 1.1% (SA) of patients with late/very late stent thrombosis (days 31-720) rates of 0.6% ( STEMI and non-STEACS) and 0.4% (SA) (P=NS). The two-year mortality rate was 2.1% ( STEMI), 4.8% (non-STEACS) and 3.7% (SA) (P=NS). Death or target vessel re- infarction occurred in 3.9% ( STEMI), 8.7% (non-STEACS) and 7.3% (SA) (P=0.012). CONCLUSION: R-ZES in STEMI and in other clinical presentations is effective and safe. Long term outcomes are favorable with an extremely rare incidence of late and very late stent thrombosis following R-ZES implantation across indications.
|
Authors | Petr Widimsky, Zuzana Motovska, Jorge Belardi, Patrick Serruys, Sigmund Silber, Stephan Windecker, Franz-Josef Neumann |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 168
Issue 4
Pg. 3522-6
(Oct 09 2013)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 23706326
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
|
Topics |
- Acute Coronary Syndrome
(diagnosis, therapy)
- Aged
- Angina, Stable
(diagnosis, therapy)
- Drug-Eluting Stents
(adverse effects)
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Myocardial Infarction
(diagnosis, therapy)
- Sirolimus
(administration & dosage, adverse effects, analogs & derivatives)
- Time Factors
- Treatment Outcome
|